GNTA: Genenta Science SpA Net earnings per share (EPS TTM)

Genenta Science S.p.A. bases its development on bioethics and environmental safety when creating cellular therapies. The change in rolling net income per share demonstrates capital dynamics, where the current value of the indicator is -0.37. High R&D expenditures and patents for viral vectors create an insurmountable barrier to entry, protecting the company's developments from new competitors in oncology.

GNTA (Genenta Science S.p.A.) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/04/2026

genenta.com - analytical breakdowns and key metrics (GNTA)

- share price and expert price forecast:

Stock Quotes Genenta Science|GNTA - Fair Value Consensus

- market capitalization information:

Market Capitalization Genenta Science S.p.A.|GNTA - Real Price to Acquire Entire Company

- business book valuation details:

Book Value per Share Genenta Science|GNTA - Total Stockholders' Equity|Market Value to Book Value Ratio genenta.com|GNTA - Aggregate Company Assets

- debt and liquidity data:

- net income and valuation multiples indicators:

GNTA - Company Profit|Projected Future Earnings Genenta Science S.p.A.|GNTA - Market Cap to Earnings|Projected Price to Earnings Genenta Science|GNTA - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Genenta Science S.p.A.|GNTA - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Genenta Science|GNTA - Earnings per share for the trailing year|Quarterly EPS earnings growth genenta.com|GNTA - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Genenta Science S.p.A.

- revenue and sales proceeds data:

GNTA - Company Sales Revenue|Projected Sales Volume Genenta Science S.p.A.|GNTA - P/S Multiple|Price-to-Projected Revenue Ratio Genenta Science SpA

General company analysis:Genenta Science SpA (GNTA)

Mass-produced product of Genenta Science S.p.A.

Genenta Science S.p.A. is investing in innovative gene therapy delivery to combat glioblastoma. Net earnings per share over the last four quarters reflect the final financial result distributed across the total volume of the issue. Growth in this indicator confirms the effectiveness of cost management while scaling clinical trials. A declining trend signals expanding operating expenses. The dynamics of this metric directly determine the investment attractiveness of the market capitalization.

Analysis of competing companies

LEGN: Net earnings per share for the last 12 months|Earnings per share for the trailing year SANA (Sana Biotechnology, Inc.)|AUTL: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Allogene Therapeutics Inc|RNAC (Selecta Biosciences) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months cellectis.com CLLS|Earnings per share for the last twelve months Caribou Biosciences, Inc. (CRBU)|Earnings per share for the last twelve months TIL (Instil Bio, Inc)|Earnings per share for the last twelve months Century Therapeutics Inc IPSC|jaspertherapeutics.com - Earnings per share for the last twelve months|SNTI: Net earnings per share for the last 12 months|Earnings per share for the trailing year ADAP (adaptimmune.com)|CERO: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Alaunos Therapeutics Inc. TCRT|ACHL (Achilles Therapeutics PLC) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CARGO Therapeutics, Inc CRGX|Earnings per share for the last twelve months Poseida Therapeutics, Inc. (PSTX)|2seventy bio, Inc. - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) GRCL (Gracell)